Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Global Forecast 2024-2030

Cancer Diagnostics Market by Diagnostic Type (Biopsy, Blood Chemistry Tests, Imaging Tests), Indication (Bladder Cancer, Blood Cancer, Breast Cancer), Components, End-Use - Global Forecast 2024-2030

The Cancer Diagnostics Market size was estimated at USD 29.95 billion in 2023 and expected to reach USD 33.31 billion in 2024, at a CAGR 11.71% to reach USD 65.06 billion by 2030.

Global Cancer Diagnostics MarketCancer diagnostics focus on detecting symptomatic patients to provide the best possible treatment immediately. There are multiple imaging tests available for cancer diagnosis, such as a computerized tomography (CT) scan, bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, ultrasound, and X-ray. The growing prevalence of cancer, significant government involvement, and favorable reimbursement policies have enhanced the adoption rate of cancer diagnostics. However, the false and inadequate results and associated high costs may hamper the market growth. Nevertheless, the ongoing advancements in cancer diagnosis equipment and integration of advanced technologies may overcome the challenge and expand the market scope in the forecast period.Regional InsightsThe American cancer diagnostics market is highly developed due to the notable prevalence of cancer and the presence of multiple advanced imaging technologies in the region. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer diagnosis. Additionally, the growing geriatric population, ongoing cancer-related research activities, and the rising burden of different types of cancer have enhanced the need for cancer diagnosis in Germany, New Zealand, the United Kingdom, and several other European nations. Moreover, the significant involvement of the European government in cancer detection and diagnosis programs has elevated the market scope. In the Asia-Pacific region, China and India are the most prevalent regions for the increasing cases of cancer patients, which has raised the need for cancer diagnostics. Furthermore, the emerging campaigns and cancer awareness programs have highlighted the need for cancer diagnostics in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., Becton, Dickinson & Company, Bio-Techne Corporation, bioMérieux SA, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Perkin Elmer, Inc., Personal Genome Diagnostics Inc., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage



This research report categorizes the Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Diagnostic Type
Biopsy
Blood Chemistry Tests
Complete Blood Count (CBC)
Cytogenetic Analysis
Immunophenotyping
Liquid Biopsy
Sputum Cytology
Tumor Marker Tests
Urine Cytology
Imaging Tests
Bone Scan
CT-Scan
Magnetic Resonance Imaging (MRI)
Nuclear Scan
Positron Emission Tomography (PET) Scan
Ultrasound
X-Rays
Indication
Bladder Cancer
Blood Cancer
Breast Cancer
Colorectal Cancer
Kidney Cancer
Liver Cancer
Lung Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Components
Consumables
Instruments
Software
End-Use
Diagnostic Laboratories
Hospitals
Research Centers
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Cancer Diagnostics Market?
4. What is the market share of the leading vendors in the Cancer Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Cancer Diagnostics Market?

Note: PDF & Excel + Online Access - 1 Year Show more